Antibody discovery opens new avenue for HIV vaccine development

A team of U.S. and South African researchers has identified and cloned an antibody that targets one of the few unchanging regions of HIV. The antibody was generated naturally by one of the rare people who are capable of fighting off the virus. Having identified and cloned the antibody, the researchers are preparing to test the vaccine in animals. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.